(Q37958036)

25 August 2017

Treating chronic lymphocytic leukemia with thalidomide and lenalidomide (English)

1 reference

chronic lymphocytic leukemia

25 August 2017

0 references

0 references

1 reference

1 reference

3

Stephan Stilgenbauer

0 references

Krzysztof Giannopoulos

series ordinal

1

object named as

Krzysztof Giannopoulos

1 reference

25 August 2017

Daniel Mertens

2

1 reference

PubMed ID

22098228

25 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

18

1 reference

25 August 2017

2857-2864

1 reference

Understanding and managing ultra high-risk chronic lymphocytic leukemia

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Importance of genetics in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

The immunodeficiency of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.635644

10.1517/14656566.2011.635644

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22098228